Zobrazeno 1 - 10
of 28
pro vyhledávání: ''
Autor:
Philippe Delvenne, Nor Eddine Sounni, Mehdi Lienard, Joan Somja, Stéphanie Gofflot, Agnès Noël, Joëlle Collignon, Guy Jerusalem, Anne-Françoise Donneau, Pierre Foidart, Hélène Schroeder, Emilie Feyereisen, Cassandre Yip, Alice Truong
Publikováno v:
British Journal of Cancer
Background: Triple-negative breast cancers (TNBC) are heterogeneous cancers with poor prognosis. We aimed to determine the clinical relevance of membrane type-4 matrix metalloproteinase (MT4-MMP), a membrane type matrix metalloproteinase that interac
Autor:
James Spicer, Patricia Roxburgh, Mark R. Middleton, Ruth Plummer, Richard H. Wilson, Heidi Giordano, T.R. Jeffry Evans, Sandra Goble, L Rhoda Molife, Véronique Diéras, Sarah Jaw-Tsai
Publikováno v:
British Journal of Cancer
Wilson, R H, Evans, T J, Middleton, M R, Molife, L R, Spicer, J, Dieras, V, Roxburgh, P, Giordano, H, Jaw-Tsai, S, Goble, S & Plummer, R 2017, ' A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours ', BJC: British Journal of Cancer, pp. 884-892 . https://doi.org/10.1038/bjc.2017.36
Wilson, R H, Evans, T J, Middleton, M R, Molife, L R, Spicer, J, Dieras, V, Roxburgh, P, Giordano, H, Jaw-Tsai, S, Goble, S & Plummer, R 2017, ' A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours ', BJC: British Journal of Cancer, pp. 884-892 . https://doi.org/10.1038/bjc.2017.36
BACKGROUND: This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and oral rucaparib, a poly(ADP-ribose) polymerase inhibitor, combined with chemotherapy in patients with advanced solid tumours.METHODS: Initially, patien
Publikováno v:
Scientific Reports.
We developed a nano-antibody targeted chemotherapy (nATC) delivery strategy in which tumor specific and clinically relevant antibodies (rituximab, anti-CD20) are non-covalently bound to the albumin scaffold of nab-paclitaxel (ABX). We define the nano
Autor:
Ty J. Lively, Jinfeng Zhang, Pei-Yau Lung, Qing-Xiang Amy Sang, Jun Liu, Kaixian Yu, Cedric Sheffield, Winston Tan, Mayassa J. Bou-Dargham
Publikováno v:
Scientific Reports
Choosing the optimal chemotherapy regimen is still an unmet medical need for breast cancer patients. In this study, we reanalyzed data from seven independent data sets with totally 1079 breast cancer patients. The patients were treated with three dif
Autor:
Frank Hilberg, Miguel Gil, Antonio González-Martín, C Rodriguez-Martin, Ander Urruticoechea, M. J. Escudero, M. Gil-Martin, Raquel Bratos, E Hernandez-Agudo, Juan Antonio Guerra, Raul Marquez, S Vlassak, Ramon Colomer, Miguel Quintela-Fandino
Publikováno v:
British Journal of Cancer
Introduction: Previous small-molecule antiangiogenics have compromised chemotherapy dose intensity in breast cancer. We present a phase I trial of a novel selective agent, nintedanib, plus standard chemotherapy in early breast cancer. Methods: Her-2-
Autor:
Elizabeth Hopper-Borge, Brian L. Egleston, Chelsy Paulose, Ekaterina V. Malofeeva, E Peiffer, Natalya Domanitskaya, K Foster, Joely D. Jacobs, Y Mahdaviyeh, Janet Wangari-Talbot, Kathy Q. Cai, Yan Zhou
Publikováno v:
British Journal of Cancer
Background: Resistance to chemotherapeutic agents is a major obstacle to cancer treatment. A group of ABC efflux pumps, the Multidrug Resistance Proteins, is a source of resistance. Herein, we investigated the role of ABCC10 in mammary tumours, given
Autor:
Joonghyun Ahn, J.H. Lee, Yunseon Choi, Soo-Youn Lee, Myung-Ju Ahn, Jong-Mu Sun, In-Gu Do, Kwang Bo Park, Jeayoun Kim
Publikováno v:
British Journal of Cancer
Background: The mammalian target of rapamycin (mTOR) pathway is dysregulated in small-cell lung cancer (SCLC) and everolimus is an oral mTOR inhibitor. Methods: This phase-1b study assessed everolimus safety at the levels of 2.5, 5, or 10 mg once dai
Autor:
W. Lu, Pei Wang, Faming Wang, X. Cheng, Xiao-yun Wan, Yan-Li Li, Xing Xie, Yuanming Shen, F. Ye
Publikováno v:
British Journal of Cancer
Chemotherapy is an extremely important therapeutic strategy in cancers, but chemo-resistance remains one of the key causal factors in cancer death and has confused worldwide scientists and oncologists longtime (Wang et al, 2010). As we know, the majo
Autor:
Julie A. DeLoia, M M Thrall, Michael J. Birrer, Chunqiao Tian, Thomas C. Krivak, Deborah K. Armstrong, C Zahn, Kathleen M. Darcy, J L Lesnock
Publikováno v:
British Journal of Cancer
Background: Breast cancer 1, early onset (BRCA1) is a tumour-suppressor gene associated with familial epithelial ovarian cancer (EOC). Reduced BRCA1 expression is associated with enhanced sensitivity to platinum-based chemotherapy. We sought to exami
Autor:
T. A. Rado, Michael A. Tortorici, Lainie P. Martin, Jamal Tarazi, Thomas A. Samuel, Ying Chen, A Starr, Sinil Kim, Roger B. Cohen, R S Herbst, Mark Kozloff, Brad Rosbrook, Anthony J. Olszanski
Publikováno v:
British Journal of Cancer
Background: Axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, enhanced the efficacy of chemotherapy in human xenograft tumour models. This phase I study investigated the safety, tolerability